Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single‐institution outcomes

Abstract

Purpose/Objectives

We analyzed outcomes after stereotactic ablative body radiotherapy for oligometastatic (1‐5 metastatic foci) head‐and‐neck squamous cell carcinoma (OM‐HNSCC).

Materials/Methods

We reviewed patients treated between 2012 and 2016. Endpoints included overall survival (OS), distant progression, and treated‐metastasis local control (TM‐LC).

Results

We analyzed 27 patients with 60 primarily metachronous metastases (81.5%). Median follow‐up was 1.6 years (0.2‐5.2). Median time from diagnosis to treatment was 1.1 years (0.08‐8.5). Overall, 44.4% had solitary, 44.4% had 2‐3, and 11.1% had >3 metastases; most metastases were in the lung (44 of 60 metastases). Median OS was 1.9 years; at 1 and 2 years, 78% and 43% were alive (14% without disease progression). Median time to progression was 0.5 years. The 1‐year and 2‐year TM‐LC rates were 75% and 57%.

Conclusions

OS is encouraging and disease‐free survival remains poor; nevertheless, patients with OM‐HNSCC may represent a more favorable subset of patients with metastatic HNSCC.

https://ift.tt/2SQHo9O